Antagonist selective modulation of adenosine A1 and A 3 receptor pharmacology by the food dye brilliant black BN: Evidence for allosteric interactions

Molecular Pharmacology

Volumn 77, Issue 4, 2010, Pages 678-686

  May, L T ^a   Briddon, S J ^a   Hill, Stephen J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (2 AMINOETHYLCARBAMOYL)METHOXYPHENYL] 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR STIMULATING AGENT; BRILLIANT BLACK FOOD DYE; FOOD DYE; UNCLASSIFIED DRUG; XAC X BY 630;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CALCIUM MOBILIZATION; CONTROLLED STUDY; DISSOCIATION; DRUG ACTIVITY; DRUG POTENCY; FLUORESCENCE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY;

ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); ALLOSTERIC REGULATION; ANIMALS; AZO COMPOUNDS; CALCIUM; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A3; XANTHINES;

EID: 77950286098     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.063065     Document Type: Article

References (40)

1. Alexander K, Niforatos W, Bianchi B, Burgard EC, Lynch KJ, Kowaluk EA, Jarvis MF, and van Biesen T (1999) Allosteric modulation and accelerated resensitization of human P2X(3) receptors by cibacron blue. J Pharmacol Exp Ther 291:1135-1142.
2. Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A, and Scammells PJ (2009) Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J Med Chem 52:4543-4547.
3. Australian Department of Health and Ageing (2007) Substances that may be used in listed medicines in Australia, Department of Health and Ageing, Therapeutic Goods Administration, Symonston, Australia. Available at http://www.tga.gov.au/cm/listsubs.pdf.
4. Baker JG and Hill SJ (2007) A comparison of the antagonist affinities for the Gi- and Gs-coupled states of the human adenosine A1-receptor. J Pharmacol Exp Ther 320:218-228.
5. Baker JG, Middleton R, Adams L, May LT, Briddon SJ, Kellam B, and Hill SJ (2010) Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands. Br J Pharmacol doi: 10.1111/j.1476-5381.2009.00488.x.
6. Baraldi PG, Zaid AN, Lampronti I, Fruttarolo F, Pavani MG, Tabrizi MA, Shryock JC, Leung E, and Romagnoli R (2000) Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor. Bioorg Med Chem Lett 10:1953-1957.
7. Briddon SJ, Middleton RJ, Cordeaux Y, Flavin FM, Weinstein JA, George MW, Kellam B, and Hill SJ (2004) Quantitative analysis of the formation and diffusion of A1-adenosine receptor-antagonist complexes in single living cells. Proc Natl Acad Sci USA 101:4673-4678.
8. Brighton PJ, Wise A, Dass NB, and Willars GB (2008) Paradoxical behavior of neuromedin U in isolated smooth muscle cells and intact tissue. J Pharmacol Exp Ther 325:154-164.
9. Bruns RF and Fergus JH (1990) Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38:939-949.
10. Burnstock G and Williams M (2000) P2 purinergic receptors: modulation of cell function and therapeutic potential. J Pharmacol Exp Ther 295:862-869.
11. Christopoulos A (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol Sci 19:351-357.
12. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
13. Cohen MV and Downey JM (2008) Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 103:203-215.
14. Cordeaux Y, Briddon SJ, Alexander SP, Kellam B, and Hill SJ (2008) Agonist-occupied A3 adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells. FASEB J 22:850-860.
15. Cordeaux Y, Briddon SJ, Megson AE, McDonnell J, Dickenson JM, and Hill SJ (2000) Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity. Mol Pharmacol 58:1075-1084.
16. Cronshaw DG, Kouroumalis A, Parry R, Webb A, Brown Z, and Ward SG (2006) Evidence that phospholipase-C-dependent, calcium-independent mechanisms are required for directional migration of T-lymphocytes in response to the CCR4 ligands CCL17 and CCL22. J Leukoc Biol 79:1369-1380.
17. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, and Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552.
18. Gao ZG, Gross AS, and Jacobson KA (2004) Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors. Life Sci 74:3173-3180.
19. Gao ZG, Melman N, Erdmann A, Kim SG, Mü ller CE, IJzerman AP, and Jacobson KA (2003) Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors. Biochem Pharmacol 65:525-534.
20. Gao ZG, Van Muijlwijk-Koezen JE, Chen A, Mü ller CE, Ijzerman AP, and Jacobson KA (2001) Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol Pharmacol 60:1057-1063.
21. Göblyös A, Gao ZG, Brussee J, Connestari R, Santiago SN, Ye K, Ijzerman AP, and Jacobson KA (2006) Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. J Med Chem 49:3354-3361.
22. B and Bräuner-Osborne H (2009) FLIPR assays of intracellular calcium in GPCR drug discovery. Methods Mol Biol 552:269-278.
23. Iredale PA, Alexander SP, and Hill SJ (1994) Coupling of a transfected human brain A1 adenosine receptor in CHO-K1 cells to calcium mobilisation via a pertussis toxin-sensitive mechanism. Br J Pharmacol 111:1252-1256.
24. Jarvis MF, Wismer CT, Schweitzer E, Yu H, van Biesen T, Lynch KJ, Burgard EC, and Kowaluk EA (2001) Modulation of BzATP and formalin induced nociception: attenuation by the P2X receptor antagonist, TNP ATP and enhancement by the P2X(3) allosteric modulator, cibacron blue. Br J Pharmacol 132:259-269.
25. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, and Lohse MJ (1998) Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 357:1-9.
26. Lazareno S and Birdsall NJ (1993) Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br J Pharmacol 109:1110-1119.
27. Leach K, Charlton SJ, and Strange PG (2007) Analysis of second messenger pathways stimulated by different chemokines acting at the chemokine receptor CCR5. Biochem Pharmacol 74:881-890.
28. Macioszek VK and Kononowicz AK (2004) The evaluation of the genotoxicity of two commonly used food colors: Quinoline Yellow (E 104) and Brilliant Black BN (E 151). Cell Mol Biol Lett 9:107-122.
29. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
30. Peng W, Cotrina ML, Han X, Yu H, Bekar L, Blum L, Takano T, Tian GF, Goldman SA, and Nedergaard M (2009) Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci USA 106:12489-12493.
31. Rhee SG (2001) Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 70:281-312.
32. Rosethorne EM, Leighton-Davies JR, Beer D, and Charlton SJ (2004) ATP priming of macrophage-derived chemokine responses in CHO cells expressing the CCR4 receptor. Naunyn Schmiedebergs Arch Pharmacol 370:64-70.
33. Roth AL, Marzola E, Rizzi A, Arduin M, Trapella C, Corti C, Vergura R, Martinelli P, Salvadori S, Regoli D, et al. (2006) Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. J Biol Chem 281:20809-20816.
34. Schulte G and Fredholm BB (2002) Signaling pathway from the human adenosine A(3) receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2. Mol Pharmacol 62:1137-1146.
35. Su X, Leon LA, Wu CW, Morrow DM, Jaworski JP, Hieble JP, Lashinger ES, Jin J, Edwards RM, and Laping NJ (2008) Modulation of bladder function by prostaglandin EP3 receptors in the central nervous system. Am J Physiol Renal Physiol 295:F984-F994.
36. Tranberg CE, Zickgraf A, Giunta BN, Luetjens H, Figler H, Murphree LJ, Falke R, Fleischer H, Linden J, Scammells PJ, et al. (2002) 2 Amino-3-aroyl-4,5-alkylthiophenes: agonist allosteric enhancers at human A(1) adenosine receptors. J Med Chem 45:382-389.
37. van den Nieuwendijk AM, Pietra D, Heitman L, Göblyös A, and IJzerman AP (2004) Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. J Med Chem 47:663-672.
38. van der Klein PA, Kourounakis AP, and IJzerman AP (1999) Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. J Med Chem 42:3629-3635.
39. Yan L, Burbiel JC, Maass A, and Mü ller CE (2003) Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 8:537-576.
40. Yoshioka N and Ichihashi K (2008) Determination of 40 synthetic food colors in drinks and candies by high-performance liquid chromatography using a short column with photodiode array detection. Talanta 74:1408-1413.